Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy
Early dexrazoxane is significantly associated with lower cardiotoxicity risk in adults with sarcoma receiving anthracycline doses >300 mg/m2. These findings support the potential benefit of early dexrazoxane use in patients at elevated risk for anthracycline-induced cardiotoxicity; however, further validation is warranted.
Authors
- William D. Tap (ORCID: https://orcid.org/0000-0001-7779-2796)
- Anthony F. Yu (ORCID: https://orcid.org/0000-0002-7120-8285)
- Joseph S. Wallins
- Sujana Movva (ORCID: https://orcid.org/0000-0002-6569-6606)
- Jennifer E. Liu (ORCID: https://orcid.org/0000-0003-1109-9926)
- I‐Hsin Lin (ORCID: https://orcid.org/0000-0002-7600-5321)
- Kristine Jang (ORCID: https://orcid.org/0009-0002-0444-7056)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1093/oncolo/oyaf370
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bristol-Myers Squibb
- Pfizer
- Memorial Sloan-Kettering Cancer Center
- PTC Therapeutics
- Ascentage Pharma
- Servier
- National Institutes of Health
- Genentech
- National Cancer Institute
- Daiichi Sankyo Europe